Medication Reference Card: Opioid Analgesic Dependence
Buprenorphine Transdermal Patch
Norspan® (5, 10, 20 mcg/hr) · Weekly patch · TGA-approved for chronic pain · S8 Authority Required
FRANZCP · Cert. Addiction Psych. · MBBS · DPM · DNB (Psychiatry) Addiction Psychiatrist v1.4 · October 2026
For Clinicians
Same partial mu-opioid agonist pharmacology as sublingual buprenorphine: high receptor affinity, slow dissociation, ceiling for respiratory depression. Transdermal delivery achieves steady-state plasma levels without peaks/troughs, reaching therapeutic concentration over 12–24 hours after first application. The key clinical advantage: at 5 mcg/hour (Norspan 5), the daily buprenorphine absorption is approximately 120 mcg/day, well below the threshold required to displace sufficient full agonist opioid to precipitate withdrawal. This allows buprenorphine to begin occupying mu-opioid receptors incrementally, forming the pharmacokinetic basis for its use in micro-induction (Bernese method).
| Patch strength | Release rate | ~Daily absorption | ~SL buprenorphine equivalent |
|---|---|---|---|
| Norspan® 5 | 5 mcg/hour | ~120 mcg/day | ~0.12 mg/day (micro-dose) |
| Norspan® 10 | 10 mcg/hour | ~240 mcg/day | ~0.25 mg/day |
| Norspan® 20 | 20 mcg/hour | ~480 mcg/day | ~0.5 mg/day |
Apply to upper outer arm, chest, or back. Rotate sites weekly. Avoid heat (electric blankets, hot baths): increases absorption unpredictably.
- Apply Norspan 5 patch while still taking current opioid
- Continue current opioid for days 1–3 (patch reaching steady-state)
- Reduce current opioid by 25–50% on day 3–5 as tolerated
- By day 5–7: cease current opioid; either continue patch and taper, or transition to SL buprenorphine/naloxone (COWS-guided: usually straightforward at this low opioid burden)
- Norspan 10 may suffice as maintenance for very low-level dependence
- Day 1: Apply Norspan 5 patch; patient remains on current opioid (e.g. oxycodone, fentanyl patch, methadone)
- Day 2: Add sublingual buprenorphine 0.2–0.4 mg; continue full agonist at usual dose
- Days 3–5: Increase SL buprenorphine by 0.4–2 mg/day per Bernese protocol
- Day 5–7: Remove patch once SL buprenorphine reaches 6–8 mg/day
- Titrate to SL maintenance (8–24 mg/day); cease full agonist over this period
The patch-specific use in addiction is supported by pharmacokinetic modelling, expert consensus, and case series rather than large RCTs. This should be disclosed to patients. The Bernese method itself (Hämmig et al. 2016) was validated with sublingual microdoses; patches are a clinically logical extension given their steady-state kinetics and lower bioavailability. Emerging micro-induction literature describes low-dose induction strategies: Weimer et al. (2021) report a hospital-based protocol, and Naren et al. (2024), a retrospective case series in a community setting, found that 23 of 32 patients transitioned from methadone to buprenorphine using a transdermal patch regimen, with all retained in treatment; the authors note the small sample and the need for further research. For the patch as maintenance in codeine dependence: clinical experience and pharmacokinetic data support adequacy of Norspan 5–10 for opioid receptor stabilisation at this dose range; formal RCT data in this specific population are lacking.
- Off-label for addiction: in Victoria, a Schedule 8 permit is needed to treat a person who is drug dependent (other states differ)
- Heat exposure (electric blankets, fever, hot baths) significantly increases transdermal absorption: counsel patients; potential toxicity risk
- Disposal: used patches retain significant residual buprenorphine: fold sticky sides together, return to pharmacy or dispose safely; keep away from children and pets
- Skin reactions: rotate application sites every 7 days; avoid irritated or broken skin
- At 5–10 mcg/hour the analgesic effect is modest: do not mistake for adequate pain treatment in opioid-tolerant patients with moderate-severe pain
- Respiratory depression risk: monitor carefully if continuing full agonist opioids concurrently during transition: the combination is intentional but requires clinical oversight
- No naloxone component (unlike Suboxone): injection misuse would be active; lower misuse potential than SL given transdermal route but not zero
- Renal and hepatic impairment: no dose adjustment required for mild-moderate disease; use with caution in severe hepatic impairment